lifestyle.thriveinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kyverna Therapeutics, Inc.
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
April 20, 2026
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
April 9, 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
March 5, 2026
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
March 3, 2026
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
February 24, 2026
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 9, 2026